XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting  
Schedule of reportable segment profit and loss including significant expense categories

Three Months Ended March 31,

    

2025

    

2024

Expenses(1):

Research and development:

Navenibart

$

11,829

$

7,136

STAR-0310

 

7,436

 

2,975

Employee expenses

 

4,650

 

3,437

General and administrative:

 

 

Program support(2)

 

 

75

Employee expenses

 

3,524

 

2,862

Stock-based compensation expense

 

3,839

 

2,754

Consulting and professional services expenses

 

3,975

 

3,490

Other segment expenses(3)

 

1,742

 

1,421

Other income, net(4)

 

(3,286)

 

(4,222)

Segment net loss

$

33,709

$

19,928

(1)The significant expense categories and amounts align with segment level information that is regularly provided to the CODM.
(2)General and administrative program support expense includes pre-commercial costs incurred in support of navenibart and STAR-0310, and patient advocacy costs incurred in support of navenibart and STAR-0310.
(3)Other segment expense includes: costs incurred in support of overall research and development activities and non-specific programs, facilities expense, office expense, insurance expense and depreciation and amortization.
(4)Other income, net, consists primarily of interest income on investments, as further described in Note 4, “Short-Term Investments”. For the three months ended March 31, 2025 and 2024, the Company recognized interest income of $3.3 million and $4.2 million, respectively.